Edaravone Dexborneol for Ischemic Stroke with Sufficient Recanalization After Thrombectomy: a Randomized Phase II Trial

Overview

Journal Nat Commun

Specialty Biology

Date 2025 Mar 11

PMID 40064868

Authors

Hui-Sheng Chen

Zi-Ai Zhao

Xin-Yu Shen

Si-Qi Qiu

Yu Cui

Jing Qiu

Wei Li

Hong Zhang

Wen-Huo Chen

Li-Hua Wang

De-Hui Zhang

Ying Chen

Yu-Tong Ma

Zong-En Gao

Shou-Chun Wang

Di Li

Hua Liu

Thanh N Nguyen

Affiliations

Soon will be listed here.

Abstract

phase II, randomized, double blinded, multi-center study aims to explore whether intravenous edaravone dexborneol (ED) could improve clinical outcomes in patients with anterior circulation stroke with successful endovascular reperfusion (ClinicalTrials.gov: NCT04667637 Eligible patients were randomly (1:1) assigned into ED, which received intravenous ED (37.5 mg, 2/day, for 12 days) or control group, which received placebo. The primary endpoint was favorable functional outcome (a modified Rankin Scale [mRS] of 0-2 at 90 days). Two hundred patients were enrolled, including 97 in ED group and 103 in control group. The proportion of patients with 90-day mRS (0-2) was 58.7% (54/92) in ED group and 52.1% (49/94) in control group (unadjusted odds ratio 1.37, [95% CI 0.76-2.44], P = 0.29). This work suggests that intravenous ED is safe, but do not statistically improve 90-day functional outcomes in patients with anterior circulation stroke with successful endovascular reperfusion.

References

Desai S, Jha R, Linfante I . Collateral Circulation Augmentation and Neuroprotection as Adjuvant to Mechanical Thrombectomy in Acute Ischemic Stroke. Neurology. 2021; 97(20 Suppl 2):S178-S184. DOI: 10.1212/WNL.0000000000012809. View

OCollins V, Macleod M, Donnan G, Horky L, van der Worp B, Howells D . 1,026 experimental treatments in acute stroke. Ann Neurol. 2006; 59(3):467-77. DOI: 10.1002/ana.20741. View

Tate W, Polding L, Kemp S, Mlynash M, Heit J, Marks M . Thrombectomy Results in Reduced Hospital Stay, More Home-Time, and More Favorable Living Situations in DEFUSE 3. Stroke. 2019; 50(9):2578-2581. PMC: 6710133. DOI: 10.1161/STROKEAHA.119.025165. View

Khatri P, Abruzzo T, Yeatts S, Nichols C, Broderick J, Tomsick T . Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology. 2009; 73(13):1066-72. PMC: 2754326. DOI: 10.1212/WNL.0b013e3181b9c847. View

Cheng B, Guo Y, Li C, Ji B, Pan Y, Chen J . Edaravone protected PC12 cells against MPP(+)-cytoxicity via inhibiting oxidative stress and up-regulating heme oxygenase-1 expression. J Neurol Sci. 2014; 343(1-2):115-9. DOI: 10.1016/j.jns.2014.05.051. View

Seker F, Qureshi M, Mohlenbruch M, Nogueira R, Abdalkader M, Ribo M . Reperfusion Without Functional Independence in Late Presentation of Stroke With Large Vessel Occlusion. Stroke. 2022; 53(12):3594-3604. DOI: 10.1161/STROKEAHA.122.039476. View

Nie X, Leng X, Miao Z, Fisher M, Liu L . Clinically Ineffective Reperfusion After Endovascular Therapy in Acute Ischemic Stroke. Stroke. 2022; 54(3):873-881. DOI: 10.1161/STROKEAHA.122.038466. View

Mizuno A, Umemura K, Nakashima M . Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion. Gen Pharmacol. 1998; 30(4):575-8. DOI: 10.1016/s0306-3623(97)00311-x. View

Tu W, Wang L . China stroke surveillance report 2021. Mil Med Res. 2023; 10(1):33. PMC: 10355019. DOI: 10.1186/s40779-023-00463-x. View

10.

Mizuma A, You J, Yenari M . Targeting Reperfusion Injury in the Age of Mechanical Thrombectomy. Stroke. 2018; 49(7):1796-1802. PMC: 6019565. DOI: 10.1161/STROKEAHA.117.017286. View

11.

Lyden P, Buchan A, Boltze J, Fisher M . Top Priorities for Cerebroprotective Studies-A Paradigm Shift: Report From STAIR XI. Stroke. 2021; 52(9):3063-3071. PMC: 8384700. DOI: 10.1161/STROKEAHA.121.034947. View

12.

Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D . Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13):1317-29. DOI: 10.1056/NEJMoa0804656. View

13.

Brugnara G, Neuberger U, Mahmutoglu M, Foltyn M, Herweh C, Nagel S . Multimodal Predictive Modeling of Endovascular Treatment Outcome for Acute Ischemic Stroke Using Machine-Learning. Stroke. 2020; 51(12):3541-3551. DOI: 10.1161/STROKEAHA.120.030287. View

14.

Savitz S, Baron J, Yenari M, Sanossian N, Fisher M . Reconsidering Neuroprotection in the Reperfusion Era. Stroke. 2017; 48(12):3413-3419. DOI: 10.1161/STROKEAHA.117.017283. View

15.

Zhang N, Komine-Kobayashi M, Tanaka R, Liu M, Mizuno Y, Urabe T . Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke. 2005; 36(10):2220-5. DOI: 10.1161/01.STR.0000182241.07096.06. View

16.

Hill M, Goyal M, Menon B, Nogueira R, McTaggart R, Demchuk A . Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020; 395(10227):878-887. DOI: 10.1016/S0140-6736(20)30258-0. View

17.

Fu Y, Wang A, Tang R, Li S, Tian X, Xia X . Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial. JAMA Neurol. 2024; . PMC: 10877503. DOI: 10.1001/jamaneurol.2023.5716. View

18.

Zaidat O, Castonguay A, Linfante I, Gupta R, Martin C, Holloway W . First Pass Effect: A New Measure for Stroke Thrombectomy Devices. Stroke. 2018; 49(3):660-666. DOI: 10.1161/STROKEAHA.117.020315. View

19.

Wang A, Jia B, Zhang X, Huo X, Chen J, Gui L . Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol. 2023; 80(8):851-859. PMC: 10294018. DOI: 10.1001/jamaneurol.2023.1871. View

20.

Almeida J, Souza G, Silva J, Saraiva S, de Oliveira Junior R, Quintans J . Borneol, a bicyclic monoterpene alcohol, reduces nociceptive behavior and inflammatory response in mice. ScientificWorldJournal. 2013; 2013():808460. PMC: 3654274. DOI: 10.1155/2013/808460. View